Optical imaging developer VisEn Medical of Woburn, MA, has released its MMPSense molecular imaging probe for real-time imaging of matrix metallopreoteinase (MMP) related activities in vivo.
The presence of MMP activity is linked to disease phenomena, including cancer propagation, invasion, and metastsis, as well as cardiovascular disease. Developed from VisEn's proprietary fluorescence imaging probe platforms, MMPSense can image MMP activity in tumors and other sites of inflammation in vivo. The probe emits fluorescence in response to MMP activity.
In May, VisEn and its distribution partner in Asia, Olympus Corporation, launched MMPSense, as well as VisEn's AngioSpark nanoparticle-based and molecular imaging probes, in Japan and other Asian markets.
By AuntMinnie.com staff writers
June 7, 2007
Related Reading
VisEn, Merck to develop molecular imaging agents, March 6, 2007
VisEn, Olympus expand distribution relationship, December 11, 2006
Olympus, VisEn ink Japanese deal, December 11, 2006
VisEn debuts optical imaging probes, March 28, 2006
Analogic to provide FMT systems to VisEn Medical, June 7, 2004
Copyright © 2007 AuntMinnie.com
